MACROGENICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
MACROGENICS, INC. (MGNX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 1.05 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-14
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 276.70K shares, a 306.18% increase year-over-year.
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 769.67K shares, a 2587.01% increase year-over-year.
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 1.01M shares, a 96.49% increase year-over-year.
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 113.93K shares, a 28.98% increase year-over-year.
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 1.22M shares, a 57.63% increase from fiscal 2024.
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 771.67K shares, a 8.41% decline from fiscal 2023.
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 842.52K shares, a 91.69% increase from fiscal 2022.
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 439.52K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 276.70K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | 1.05M shares 10-Q · filed 2026-08-14 | 2.05M shares derived: sum of 3 quarters · filed 2026-08-14 | 2.17M shares derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | 769.67K shares 10-Q · filed 2026-05-13 | 1.78M shares derived: sum of 2 quarters · filed 2026-05-13 | 1.89M shares derived: sum of 3 quarters · filed 2026-05-13 | 1.96M shares derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | 1.01M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | 1.12M shares derived: sum of 2 quarters · filed 2026-03-09 | 1.19M shares derived: sum of 3 quarters · filed 2026-03-09 | 1.22M shares 10-K · filed 2026-03-09 |
| 2025-09-30 | 113.93K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 182.05K shares derived: sum of 2 quarters · filed 2025-11-12 | 210.69K shares 10-Q · filed 2025-11-12 | 722.54K shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 68.12K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 96.77K shares 10-Q · filed 2025-08-14 | 608.62K shares derived: sum of 3 quarters · filed 2025-08-14 | 696.95K shares derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | 28.64K shares 10-Q · filed 2025-05-13 | 540.50K shares derived: sum of 2 quarters · filed 2025-05-13 | 628.83K shares derived: sum of 3 quarters · filed 2025-05-13 | 776.50K shares derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | 511.85K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | 600.18K shares derived: sum of 2 quarters · filed 2025-03-20 | 747.86K shares derived: sum of 3 quarters · filed 2025-03-20 | 771.67K shares 10-K · filed 2025-03-20 |
| 2024-09-30 | 88.33K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | 236.01K shares derived: sum of 2 quarters · filed 2024-11-05 | 259.82K shares 10-Q · filed 2024-11-05 | 735.28K shares derived: sum of 4 quarters · filed 2024-11-05 |
| 2024-06-30 | 147.68K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | 171.49K shares 10-Q · filed 2024-08-06 | 646.95K shares derived: sum of 3 quarters · filed 2024-08-06 | 811.28K shares derived: sum of 4 quarters · filed 2024-08-06 |
| 2024-03-31 | 23.81K shares 10-Q · filed 2024-05-09 | 499.27K shares derived: sum of 2 quarters · filed 2024-05-09 | 663.61K shares derived: sum of 3 quarters · filed 2024-05-09 | 783.69K shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 475.46K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | 639.80K shares derived: sum of 2 quarters · filed 2024-03-07 | 759.88K shares derived: sum of 3 quarters · filed 2024-03-07 | 842.52K shares 10-K · filed 2024-03-07 |
| 2023-09-30 | 164.33K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | 284.42K shares derived: sum of 2 quarters · filed 2023-11-06 | 367.05K shares 10-Q · filed 2023-11-06 | 539.34K shares derived: sum of 4 quarters · filed 2023-11-06 |
| 2023-06-30 | 120.08K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 202.72K shares 10-Q · filed 2023-08-09 | 375.00K shares derived: sum of 3 quarters · filed 2023-08-09 | 432.16K shares derived: sum of 4 quarters · filed 2023-08-09 |
| 2023-03-31 | 82.64K shares 10-Q · filed 2023-05-09 | 254.92K shares derived: sum of 2 quarters · filed 2023-05-09 | 312.08K shares derived: sum of 3 quarters · filed 2023-05-09 | 488.46K shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | 172.28K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | 229.44K shares derived: sum of 2 quarters · filed 2023-03-15 | 405.82K shares derived: sum of 3 quarters · filed 2023-03-15 | 439.52K shares 10-K · filed 2023-03-15 |
| 2022-09-30 | 57.16K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 233.54K shares derived: sum of 2 quarters · filed 2022-11-03 | 267.24K shares 10-Q · filed 2022-11-03 | |
| 2022-06-30 | 176.38K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 210.08K shares 10-Q · filed 2022-08-08 | ||
| 2022-03-31 | 33.70K shares 10-Q · filed 2022-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |